Drug Profile
Camostat mesilate - Ono Pharmaceutical
Alternative Names: Camostat mesylate; Foipan; FOY-305; ono 305Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Developer Ono Pharmaceutical; Sagent Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antiulcers; Antivirals; Benzene derivatives; Guanidines; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Peptide hydrolase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pancreatitis; Reflux oesophagitis
- Phase II/III COVID 2019 infections
- Discontinued Cancer
Most Recent Events
- 20 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes phase-II/III ACTIV-2 trial in COVID-2019 infections in USA, Argentina, Brazil, Canada, South Africa, Mexico, Philippines and Puerto Rico (PO) (NCT04518410)
- 27 May 2022 Latus Therapeutics in collaboration with Cancer Research terminates a phase-II/III trial in COVID-2019 infections in United Kingdom (PO) (EudraCT2020-002110-41) (NCT04455815)
- 30 Mar 2022 Efficacy and safety data from a phase II trial in COVID-2019 infections at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)